Abbott Laboratories Pakistan Limited · PSX:ABOT
Abbott Laboratories Pakistan — Q3 2021 Earnings Presentation
19 slides from Abbott Laboratories Pakistan's earnings presentation, Dec 17, 2021
Slide 1: Corporate Briefing Session - 2021
Corporate Briefing Session - 2021 December 17, 2021
Slide 2: Table of Contents
Abbott Pakistan - Analyst Briefing – Q3 2021 Table of Contents • Company Overview • Economic Overview • Financial Results for 2020 • Financial Results for Q3 2021 • Q&A pk.abbott.com
Slide 3: Company Overview
Abbott Pakistan - Analyst Briefing – Q3 2021 Company Overview Incorporated on July 02, 1948 1962 – Set up Other segments manufacturing Two manufacturing (mainly includes facility in Karachi general health and listed as public facilities care and diabetes) limited company in 1982 Abbott Laboratories
Slide 4: Pakistan – Macro Economic Overview
PAKISTAN – MACRO ECONOMIC OVERVIEW Gross Domestic Product Growth (GDP%) 6% • GDP growth FY21 - registered 3.94%, a V-shape recovery 5.30% 5.50% supported by the macroeconomic policies of government and 5% 4.50% SBP. 4.10% 4.10% 3.94% 4% 3.60% 3.80% 3.70% • Future outlook for growth — projected by Go
Slide 5: Inflow & Outflow
INFLOW & OUTFLOW CURRENT ACCOUNT DEFICIT 5M - FY22 USD IN BILLION Imports 5M-FY22: Workers 12.90 ↑10% • Increased by 69% from same period last year ' Remittance 11.77 • A steep rise in global freight rates. • Increase in commodity prices increased food 20.59↑112% Trade Deficit imports. 9.72 • Increa
Slide 6: Foreign Exchange – USD / PKR Parity Round Up
FOREIGN EXCHANGE – USD / PKR PARITY ROUND UP USD/PKR Movement Market Driven Flexible Regime – USD/PKR parity 177.98 effect since May 2019 onwards. Free-Float Exchange Rate Regime 25.97% devaluation Widening Current Account Deficit – main reason for the recent PKR depreciation against the USD (12.74%
Slide 7: Financial Results - 2020
Financial Results - 2020
Slide 8: Key Highlights – FY2020
Abbott Pakistan - Analyst Briefing – Q3 2021 Key Highlights – FY2020 • Overall revenue of the Company increased by 17% reaching Rs. 35.28 bn. Rs. 35.28bn 17% Sales Revenue Sales Growth • Increase in profitability mainly on account of improved performance of our Pharma and Nutritional segment. • Earn
Slide 9: Revenue Analysis – FY20
Abbott Pakistan - Analyst Briefing – Q3 2021 Revenue Analysis – FY20 36,000 35,000 35,283 Segment wise Revenue 34,000 17% (PKR in millions) PKR in million 33,000 32,000 31,000 30,156 Segment 2020 2019 % Increase 30,000 29,000 28,000 27,000 26,000 2019 2020 Pharmaceutical 23,877 21,202 13% Revenue ➢
Slide 10: Segment Gross Profit analysis – FY20
Abbott Pakistan - Analyst Briefing – Q3 2021 Segment Gross Profit analysis – FY20 13,000 Segment GP 12,222 12,000 Segment-wise GP (PKR in millions) 11,000 PKR in million 10,000 Segment 2020 GP % 2019 GP % 9,000 8,528 8,000 Pharmaceutical 7,305 31% 6,058 29% 7,000 2019 2020 Nutritional 3,913 46% 1,54
Slide 11: Financial Results – Q3 2021
Financial Results – Q3 2021
Slide 12: Key Highlights – Q3 2021
Abbott Pakistan - Analyst Briefing – Q3 2021 Key Highlights – Q3 2021 • Overall revenue of the Company increased by 26% reaching Rs. 31.45 bn. Rs. 31.45bn 26% • Sales increased on account of Sales Revenue Sales Growth increase in overall volume by 18% and price by 8%. • Profitability driven by produ
Slide 13: Revenue Analysis – Q3 2021
Abbott Pakistan - Analyst Briefing – Q3 2021 Revenue Analysis – Q3 2021 32,000 Sales 31,447 Segment wise Revenue 31,000 30,000 29,000 (PKR in millions) 26% 28,000 PKR in million 27,000 26,000 Jan - Sep Jan - Sep 24,972 Segment % Increase 25,000 2021 2020 24,000 23,000 22,000 21,000 Pharmaceutical 20
Slide 14: Segment Gross Profit analysis – Q3 2021
Abbott Pakistan - Analyst Briefing – Q3 2021 Segment Gross Profit analysis – Q3 2021 Segment GP 14,000 12,000 12,132 Segment-wise GP (PKR in millions) 10,000 PKR in million 8,661 Jan - Sep Jan - Sep 8,000 Segment 2021 GP % 2020 GP % 6,000 4,000 Pharmaceutical 7,378 37% 5,487 32% 2,000 Q3 2020 Q3 202
Slide 15: Statement of Profit or Loss – Q3 2021
Abbott Pakistan - Analyst Briefing – Q3 2021 Statement of Profit or Loss – Q3 2021 Jan - Sep Jan - Sep Variance – Favorable / Description % % 2021 2020 (Unfavorable) Rupees in millions % Sales 100 31,447 100 24,972 6,475 26 Cost of Sales 61 19,315 65 16,311 3,004 (18) Gross Profit 39 12,132 35 8,661
Slide 16: Key Financial Ratios
Abbott Pakistan - Analyst Briefing – Q3 2021 Key Financial Ratios Ratio Unit Sep – 2021 Sep – 2020 Profit Margins Profitability Ratios 45.0% Gross profit margin % 38.6 34.7 38.6% 40.0% 34.7% 35.0% Net profit margin % 14.3 12.4 30.0% Return on Equity % 28.5 21.6 25.0% 20.0% 14.3% Return on assets % 1
Slide 17: Statement of Financial Position – Sep 30, 2021
Abbott Pakistan - Analyst Briefing – Q3 2021 Statement of Financial Position – Sep 30, 2021 Description Sep 2021 Dec 2020 Variance Description Sep 2021 Dec 2020 Variance Rupees in Millions % Rupees in Millions % Non-current assets Share capital and reserves Property, plant and equipment 9,653 9,070
Slide 18: Q&A
Q&A
Slide 19: Thank you
Thank you
Abbott Laboratories (Pakistan) — Q3 2021 Earnings Presentation on 6ix